Physician profile
Donovan K Brown
NPI 1760483523
$1,773.22
in general payments reported to CMS, 2019-2025
26 companies · $117 in 2025
The $117 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $260 · 2020: $144 · 2021: $434 · 2022: $158 · 2023: $388 · 2024: $274 · 2025: $117.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $778.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $778.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $371.29 | 2019-2022 | |
| Novo Nordisk INC | $211.58 | 2022-2025 | Ozempic, Rybelsus |
| E.R. Squibb & Sons, L.L.C. | $167.95 | 2019-2022 | |
| Pfizer INC. | $163.20 | 2019-2022 | |
| Beckman Coulter, INC. | $115.51 | 2021-2023 | Dxi 800 |
| Abbvie INC. | $113.89 | 2021-2024 | |
| Amgen INC. | $97.89 | 2024-2025 | Repatha, Otezla, Repatha |
| Novartis Pharmaceuticals Corporation | $61.06 | 2019-2023 | |
| Glaxosmithkline, LLC. | $59.25 | 2023-2024 | Trelegy Ellipta |
| Astrazeneca Pharmaceuticals Lp | $50.42 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $48.04 | 2023 | Quviviq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $45.70 | 2023-2024 | Xifaxan |
| Halozyme INC | $28.51 | 2023 | |
| Antares Pharma, INC. | $28.06 | 2024 | Xyosted |
| Melinta Therapeutics, LLC | $24.24 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $23.08 | 2023 | Veozah |
| Sumitomo Pharma America, INC. | $20.20 | 2023 | Gemtesa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.07 | 2024 | Jardiance |
| Almatica Pharma LLC | $18.36 | 2024 | Teriparatide, Loreev Xr |
| Evoke Pharma, INC. | $17.31 | 2023 | Gimoti |
| Valeritas, INC. | $16.67 | 2019 | |
| Axsome Therapeutics, INC. | $16.11 | 2025 | Auvelity |
| Abbott Laboratories | $15.75 | 2023 | Freestyle Libre 3 |
| Exact Sciences Corporation | $14.72 | 2025 | The Cologuard Plus Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $13.86 | 2023 | |
| Clarus Therapeutics INC. | $11.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donovan Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.